Bristol-Myers shares drop; Regenera offers a lifeline to sinking Alcobra
→ The reverberations continue from Bristol-Myers Squibb’s missteps with Opdivo earlier this year. Shares dropped four percent this week as rumors of a potential sale once again began to swirl, Bloomberg reports. Immuno-oncology and drug combinations are primary focuses for Bristol-Myers Squibb.
→ Regenera shareholders have offered to buy shares of Alcobra for 66.6% of the combined company. Alcobra is running out of options since it hasn’t recovered from the failure of its ADHD drug in September 2014.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
